Research statistics

Orforglipron research: publications and trials

What has been published on Orforglipron: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Orforglipron works or is safe. For what it is and what the studies found, see the Orforglipron profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

130

Since 2020

Publications in 2026 so far

78

Through November 15, 2026

Human clinical research

25.8%

33 of 128 classified

Registered clinical trials

53

ClinicalTrials.gov

Randomized controlled trials

24

Publications reporting an RCT in people

Systematic reviews and meta-analyses

25

Preclinical studies

6.3%

4 animal · 2 in vitro · 2 computational

Records that only mention it

32

Not counted above

Status in the library: FDA-approved. Groups: GLP-1 receptor agonists. 2 publications are not yet classified by study type.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.
  • Not a peptide: it is shown for completeness and left out of every peptide total.

Publications by year

Orforglipron publications by year and evidence

2020, Preclinical (animal, in vitro, computational): 1 of 12023, Human clinical research: 5 of 122023, Reviews and meta-analyses: 1 of 122023, Other and not yet classified: 6 of 122024, Human clinical research: 1 of 122024, Preclinical (animal, in vitro, computational): 1 of 122024, Reviews and meta-analyses: 10 of 122025, Human clinical research: 8 of 272025, Reviews and meta-analyses: 12 of 272025, Other and not yet classified: 7 of 272026 (to date), Human clinical research: 19 of 782026 (to date), Preclinical (animal, in vitro, computational): 6 of 782026 (to date), Reviews and meta-analyses: 36 of 782026 (to date), Other and not yet classified: 17 of 78Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified02040608020202023202420252026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
202001001
2023501612
20241110012
20258012727
2026 (to date)196361778

Study types

Review34
Editorial, letter or other28
Randomized controlled trial24
Systematic review13
Meta-analysis12
Other clinical trial7
Animal study4
Computational study2
In vitro study2
Observational human study2
Not yet classified2

Research areas

From MeSH major topics. A paper can be in several areas.

Metabolic health95
Obesity and weight management75
Endocrinology51
Cardiovascular20
Gastrointestinal10
Neurological and mental health5
Musculoskeletal2
Longevity and aging1
Reproductive and sexual health1

Registered clinical trials

1 of 29 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 33 · Recruiting: 9 · Active, not recruiting: 8 · Not yet recruiting: 3
Phase 1: 22 · Phase 2: 2 · Phase 3: 27 · Phase 4: 2

TrialStatusPhaseStartedResults
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health ProblemsNCT07790861 · 192 enrolledNot yet recruitingPhase 32026-12—
Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy DiscontinuationNCT07729332 · 60 enrolledNot yet recruitingPhase 42026-11—
PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic ResponsesNCT07739537 · 100 enrolledNot yet recruitingPhase 42026-10—
IBI3042 Study in Healthy Participants and Overweight or Obese ParticipantsNCT07793019 · 104 enrolledRecruitingPhase 12026-09—
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 ObesityNCT07794579 · 2,001 enrolledRecruitingPhase 32026-08—
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan FastingNCT07613307 · 130 enrolledRecruitingPhase 32026-07—
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 DiabetesNCT07668336 · 170 enrolledRecruitingPhase 32026-07—
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)NCT07241390 · 7,140 enrolledRecruitingPhase 32025-12—
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery DiseaseNCT07223593 · 1,205 enrolledRecruitingPhase 32025-10—
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or OverweightNCT07202884 · 1,000 enrolledRecruitingPhase 32025-09—
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the KneeNCT07153471 · 800 enrolledActive, not recruitingPhase 32025-09—
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 DiabetesNCT06972472 · 600 enrolledActive, not recruitingPhase 32025-05—
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityNCT06972459 · 800 enrolledActive, not recruitingPhase 32025-05—
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesNCT06993792 · 1,400 enrolledActive, not recruitingPhase 32025-05—
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)NCT06948422 · 974 enrolledActive, not recruitingPhase 32025-04—
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1NCT06948435 · 487 enrolledActive, not recruitingPhase 32025-04—
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2NCT06952530 · 487 enrolledActive, not recruitingPhase 32025-04—
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or OverweightNCT06824051 · 120 enrolledCompletedPhase 12025-02—
A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy ParticipantsNCT06692348 · 86 enrolledCompletedPhase 12024-12—
A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy ParticipantsNCT06704763 · 27 enrolledCompletedPhase 12024-12Posted
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)NCT06672549 · 125 enrolledRecruitingPhase 32024-11—
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesNCT06672939 · 150 enrolledRecruitingPhase 32024-11—
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045 · 712 enrolledCompletedPhase 32024-10—
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)NCT06584916 · 376 enrolledCompletedPhase 32024-09—
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or OverweightNCT06440980 · 533 enrolledCompletedPhase 12024-06Posted
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy ParticipantsNCT06370728 · 30 enrolledCompletedPhase 12024-05Posted
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With MetforminNCT06192108 · 962 enrolledCompletedPhase 32024-01Posted
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese ParticipantsNCT06186622 · 50 enrolledCompletedPhase 12024-01Posted
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 InhibitorNCT06109311 · 546 enrolledCompletedPhase 32023-11Posted
A Phase I Study of LY3502970 in Healthy ParticipantsNCT06085482 · 10 enrolledCompletedPhase 12023-10Posted
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 DiabetesNCT06010004 · 401 enrolledCompletedPhase 32023-09Posted
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminNCT06045221 · 1,698 enrolledCompletedPhase 32023-09Posted
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related ComorbiditiesNCT06023095 · 24 enrolledCompletedPhase 12023-09Posted
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneNCT05971940 · 559 enrolledCompletedPhase 32023-08Posted
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity DiseaseNCT05931380 · 238 enrolledCompletedPhase 32023-07Posted
A Phase 1, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Renal Function and Participants With Renal Impairment.NCT05936138 · 24 enrolledCompletedPhase 12023-07Posted
A Study of LY3502970 in Participants With Impaired and Normal Liver FunctionNCT05882032 · 29 enrolledCompletedPhase 12023-06Posted
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903 · 3,127 enrolledActive, not recruitingPhase 32023-06Posted
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesNCT05872620 · 1,613 enrolledCompletedPhase 32023-06Posted
A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese ParticipantsNCT05841238 · 52 enrolledCompletedPhase 12023-04Posted
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular RiskNCT05803421 · 2,749 enrolledCompletedPhase 32023-04—
A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy ParticipantsNCT05573230 · 32 enrolledCompletedPhase 12022-10Posted
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy ParticipantsNCT05469126 · 26 enrolledCompletedPhase 12022-08Posted
A Study of LY3502970 in Healthy Overweight and Obese ParticipantsNCT05313802 · 72 enrolledCompletedPhase 12022-05Posted
A Study of Two Different Formulations of LY3502970 in Healthy ParticipantsNCT05341089 · 39 enrolledCompletedPhase 12022-05Posted
A Study of LY3502970 in Japanese Participants With Type 2 Diabetes MellitusNCT05086445 · 62 enrolledCompletedPhase 12021-11Posted
A Multiple-Dose Study of LY3502970 in Healthy ParticipantsNCT05110794 · 34 enrolledCompletedPhase 12021-11Posted
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related ComorbiditiesNCT05051579 · 272 enrolledCompletedPhase 22021-09Posted
A Multiple Dose Study of LY3502970 in Healthy ParticipantsNCT05051566 · 26 enrolledCompletedPhase 12021-09Posted
A Study of LY3502970 in Participants With Type 2 Diabetes MellitusNCT05048719 · 383 enrolledCompletedPhase 22021-09Posted

The 50 most recently started of 53 trials.

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis.

    BMC endocrine disorders · September 15, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42750018 · DOI 10.1186/s12902-026-02538-x · Reviews and meta-analyses

  2. Exploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis.

    High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · July 15, 2026 · Meta-analysis · cited 1 times

    PMID 42458197 · DOI 10.1007/s40292-026-00814-4 · Reviews and meta-analyses

  3. Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison.

    Diabetes, obesity & metabolism · June 1, 2026 · Meta-analysis · cited 3 times · open access

    PMID 42225305 · DOI 10.1111/dom.70919 · Reviews and meta-analyses

  4. Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis.

    Diabetes technology & therapeutics · February 4, 2026 · Meta-analysis · cited 3 times

    PMID 41640110 · DOI 10.1177/15209156261420404 · Reviews and meta-analyses

  5. Efficacy and safety of orforglipron in type 2 diabetes mellitus and obesity: a GRADE-assessed meta-analysis and trial sequential analysis with subgroup evaluations by diabetic status, obesity status, and dose regimens.

    Acta diabetologica · January 7, 2026 · Meta-analysis · cited 3 times

    PMID 41498807 · DOI 10.1007/s00592-025-02635-8 · Reviews and meta-analyses

  6. The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.

    Frontiers in endocrinology · December 10, 2025 · Meta-analysis · cited 3 times · open access

    PMID 41450584 · DOI 10.3389/fendo.2025.1646956 · Reviews and meta-analyses

  7. Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis.

    Medicine · December 1, 2025 · Meta-analysis · cited 5 times · open access

    PMID 41465949 · DOI 10.1097/md.0000000000046671 · Reviews and meta-analyses

  8. Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta-Analysis.

    Endocrinology, diabetes & metabolism · November 1, 2025 · Meta-analysis · cited 9 times · open access

    PMID 41296780 · DOI 10.1002/edm2.70134 · Reviews and meta-analyses

  9. Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis.

    Diabetes technology & therapeutics · February 6, 2025 · Meta-analysis · cited 10 times

    PMID 39911047 · DOI 10.1089/dia.2024.0533 · Reviews and meta-analyses

  10. Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials.

    Obesity pillars · January 30, 2025 · Meta-analysis · cited 32 times · open access

    PMID 39980735 · DOI 10.1016/j.obpill.2025.100162 · Reviews and meta-analyses

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.

    The New England journal of medicine · June 23, 2023 · Randomized controlled trial · cited 473 times

    PMID 37351564 · DOI 10.1056/nejmoa2302392 · Human clinical research

  2. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.

    Proceedings of the National Academy of Sciences of the United States of America · November 11, 2020 · In vitro study · cited 225 times · open access

    PMID 33177239 · DOI 10.1073/pnas.2014879117 · In vitro studies

  3. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.

    Lancet (London, England) · June 24, 2023 · Randomized controlled trial · cited 183 times

    PMID 37369232 · DOI 10.1016/s0140-6736(23)01302-8 · Human clinical research

  4. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.

    The New England journal of medicine · September 16, 2025 · Randomized controlled trial · cited 180 times

    PMID 40960239 · DOI 10.1056/nejmoa2511774 · Human clinical research

  5. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.

    The New England journal of medicine · June 21, 2025 · Randomized controlled trial · cited 127 times

    PMID 40544435 · DOI 10.1056/nejmoa2505669 · Human clinical research

Latest publications

  1. Association Between Orforglipron and Blood Pressure in Adults With Obesity With or Without Type 2 Diabetes: Post Hoc Analyses From ATTAIN-1 and ATTAIN-2 Trials.

    Diabetes, obesity & metabolism · November 10, 2026 · Other clinical trial · cited 0 times · open access

    PMID 43010686 · DOI 10.1111/dom.71543 · Human clinical research

  2. Orforglipron for Obstructive Sleep Apnea: Research Summary.

    JAMA · November 9, 2026 · Not yet classified · cited 0 times

    PMID 43002163 · DOI 10.1001/jama.2026.24226 · Not yet classified

  3. Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA).

    JAMA · November 9, 2026 · Randomized controlled trial · cited 1 times

    PMID 43002161 · DOI 10.1001/jama.2026.24080 · Human clinical research

  4. [New oral anti-obesity drugs: the future or second choice?]

    Innere Medizin (Heidelberg, Germany) · November 3, 2026 · Review · cited 0 times

    PMID 42977781 · DOI 10.1007/s00108-026-02204-3 · Reviews and meta-analyses

  5. In T2D inadequately controlled with metformin, orforglipron reduced HbA<sub>1c</sub> more than dapagliflozin at 40 wk.

    Annals of internal medicine · November 3, 2026 · Not yet classified · cited 0 times

    PMID 42970798 · DOI 10.7326/annals-26-04099-jc · Not yet classified

  6. Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial.

    The lancet. Diabetes & endocrinology · October 30, 2026 · Randomized controlled trial · cited 0 times

    PMID 42962687 · DOI 10.1016/s2213-8587(26)00232-9 · Human clinical research

  7. Orforglipron for Type 2 Diabetes and Pancreatic Risk Assessment.

    JAMA · October 26, 2026 · Editorial, letter or other · cited 0 times

    PMID 42931747 · DOI 10.1001/jama.2026.18104 · Commentary and other

  8. Orforglipron for Type 2 Diabetes and Pancreatic Risk Assessment-Reply.

    JAMA · October 26, 2026 · Editorial, letter or other · cited 0 times

    PMID 42931748 · DOI 10.1001/jama.2026.18107 · Commentary and other

  9. Oral Versus Injectable Incretin-Based Anti-Obesity Therapies: An Integrated Computational and Evidence-Based Comparison of Orforglipron, Semaglutide, and Tirzepatide.

    Omics : a journal of integrative biology · October 20, 2026 · Computational study · cited 0 times

    PMID 42902597 · DOI 10.1177/15578100261499499 · Computational studies

  10. Qualitative Exit Interviews to Characterize the Positive Treatment Experiences of Patients in the Phase III Trial of Orforglipron Versus Oral Semaglutide for the Treatment of Type 2 Diabetes.

    The patient · October 16, 2026 · Observational human study · cited 0 times · open access

    PMID 42888373 · DOI 10.1007/s40271-026-00847-w · Human clinical research

Browse all 130 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Foundayo; LY3502970; Orforglipron

((TITLE_ABS:"Foundayo" OR CHEM:"Foundayo") OR (TITLE_ABS:"LY3502970" OR CHEM:"LY3502970" OR TITLE_ABS:"LY 3502970" OR CHEM:"LY 3502970") OR (TITLE_ABS:"Orforglipron" OR CHEM:"Orforglipron")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Orforglipron research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/orforglipron